SII Gets Nod For The Oxford Coronavirus Vaccine From DGCI

August 03, 2020 15:49
SII Gets Nod For The Oxford Coronavirus Vaccine From DGCI

(Image source from:

SII Gets Nod For The Oxford Coronavirus Vaccine From DGCI:- The Drug Controller General of India (DGCI) gave its nod for Serum Institute of India (SII) to conduct the second and third phase of the clinical trials of coronavirus vaccine that is developed by Oxford University. After a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC), Dr VG Somani granted the permission for the second and third phase of clinical trials for coronavirus vaccine. The evaluation was done by Data Safety Monitoring Board (DSMB) said a senior official. Each subject would be given two doses of the vaccine in four weeks. The first dose is given on day one and the second dose on 29th day.

SII which is said to be the world's largest vaccine maker inked a deal with the University of Oxford’s Jenner Institute in collaboration with British-Swedish company AstraZeneca for the coronavirus vaccine. The vaccine developed by Oxford University is one of the best vaccines and the trials are extremely positive. The second and third phase of trials are happening in United Kingdom. Brazil is in the third phase of trials and South Africa is currently undergoing phase one and two trials. Serum Institute of India submitted a revised proposal and the results were positive.

SII said that 1600 people across the country who are above the age of 18 years will participate in the clinical trials. These trials will take place across 17 Indian cities.

If you enjoyed this Post, Sign up for Newsletter

(And get daily dose of political, entertainment news straight to your inbox)

Rate This Article
(0 votes)
Tagged Under :
SII clinical trials  DGCI  SII  Coronavirus